Companies Gritstone bio
Gritstone bio (GRTS): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Gritstone bio no longer files a proxy statement; its last pay data is FY2023.
CEO pay, last three years
- $2,868,676FY2022
- $3,444,071FY2023
CEO total pay was $3,444,071 in fiscal 2023, up from $2,868,676 in fiscal 2022.
FY2023: salary $645,833 · bonus $0 · stock awards $2,429,830 · option awards $0
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Andrew Allen | $645,833 | $0 | $2,429,830 | $0 | $355,208 | $0 | $13,200 | $3,444,071 |
| President and Chief Executive Officer | ||||||||
| Karin Jooss | 525,000 | 0 | 831,590 | 0 | 210,000 | 0 | 13,200 | 1,579,790 |
| Executive Vice President and Head of Research & Development | ||||||||
| Erin Jones | 483,333 | 0 | 831,860 | 0 | 193,333 | 0 | 13,200 | 1,521,727 |
| Executive Vice President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Andrew Allen | $3,444,071 | $2,868,676 | — | ↑ +575,395 |
| Karin Jooss | 1,579,790 | 1,463,841 | — | ↑ +115,949 |
| Erin Jones | 1,521,727 | 1,403,946 | — | ↑ +117,781 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our named executive officer compensation program in 2023 was designed to align executive compensation with our performance, with an emphasis on long-term equity compensation. We reward our named executive officers with competitive compensation packages that directly align pay with performance, specifically the degree to which named executive officers are granted equity and earn bonuses based on research, clinical, and regulatory milestones.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Karin Jooss | Option | 6,875 | — | — |
| Erin Jones | Option | 8,750 | — | — |
| Andrew Allen | Option | 17,188 | — | — |
| Karin Jooss | Option | 31,250 | — | — |
| Erin Jones | Option | 31,250 | — | — |
| Karin Jooss | RSU | 82,397 | — | 168,090 |
| Erin Jones | RSU | 82,479 | — | 168,257 |
| Erin Jones | Option | 84,903 | — | — |
| Karin Jooss | Option | 86,250 | — | — |
| Andrew Allen | Option | 90,625 | — | — |
| Karin Jooss | RSU | 149,070 | — | 304,103 |
| Erin Jones | RSU | 149,070 | — | 304,103 |
| Andrew Allen | Option | 213,542 | — | — |
| Andrew Allen | RSU | 239,309 | — | 488,190 |
| Andrew Allen | RSU | 436,836 | — | 891,145 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Elaine Jones, Ph.DIndependent · Board Chair · Audit · Compensation | $87,500 | $0 | $88,499 | — | — | $175,999 |
| Steve KrognesIndependent · Audit (Chair) · Compensation · Not standing for re-election | 60,000 | 0 | 88,499 | — | — | 148,499 |
| Naiyer Rizvi, M.DIndependent · Audit · Nominating and Corporate Governance | 51,500 | 0 | 88,499 | — | — | 139,999 |
| Shefali Agarwal, M.D., M.P.HIndependent · Compensation (Chair) | 50,000 | 0 | 88,499 | — | — | 138,499 |
| Clare FisherIndependent · Nominating and Corporate Governance (Chair) | 48,000 | 0 | 88,499 | — | — | 136,499 |
| Lawrence Corey, M.DIndependent · Nominating and Corporate Governance | 44,000 | 0 | 88,499 | — | — | 132,499 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,500 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $341,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $341,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Gritstone bio as a peer
Companies that benchmark against GRTS
2 companies name GRTS as a compensation peer
- SUTRO BIOPHARMA, INC.STROFY2025
Each company listed discloses GRTS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GRTS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Peer reciprocity
The companies Gritstone bio names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Inc. | 2026 | Eric Venker | $636,618 | $0 | $19,010,639 | $0 | $20,158,767 |
| 2 | Replimune Group, Inc. | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 3 | CytomX Therapeutics, Inc. | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 4 | Kura Oncology Inc. | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 5 | Poseida Therapeutics, Inc. | 2023 | Mark Gergen | 611,667 | 1,442,285 | 1,413,936 | 336,420 | 3,818,018 |
| 6 | Gritstone bio | 2023 | Andrew Allen | 645,833 | 2,429,830 | 0 | 355,208 | 3,444,071 |
| 7 | IGM Biosciences, Inc. | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 8 | Precision BioSciences, Inc. | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 9 | Evelo Biosciences, Inc. | 2022 | Balkrishan Gill | 585,000 | 0 | 1,136,250 | 0 | 1,721,635 |
| 10 | Arcturus Therapeutics Inc. | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
| 11 | Sutro Biopharma, Inc. | 2025 | William Newell | 239,693 | 0 | 0 | 0 | 1,671,311 |
| 12 | Jounce Therapeutics, Inc. | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 13 | Arbutus Biopharma Corporation | 2025 | Lindsay Androski | 437,750 | 0 | 714,751 | 216,512 | 1,369,013 |
| 14 | Atara Biotherapeutics Inc. | 2025 | AnhCo Nguyen | 668,800 | 0 | 0 | 0 | 1,068,069 |
| 15 | Celularity Inc. | 2024 | Robert Hariri | 179,140 | — | 634,563 | — | 848,959 |
| — | Finch Therapeutics Group, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Vaxart Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Gritstone bio | not disclosed | RSU 100 | not disclosed | Aon |
| Arbutus Biopharma Corporation | 110% of target% | not disclosed | not disclosed | Radford (Aon) |
| Arcturus Therapeutics Inc. | not disclosed | Options 100 | not disclosed | not disclosed |
| Atara Biotherapeutics Inc. | not disclosed | RSU 100 | not disclosed | Pearl Meyer |
| Celularity Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | not disclosed |
| CytomX Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Evelo Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Pay Governance LLC |
| Finch Therapeutics Group, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| IGM Biosciences, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Immunovant Inc. | 110% | not disclosed | No | Compensia |
| Jounce Therapeutics, Inc. | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Kura Oncology Inc. | 150% | not disclosed | No | Alpine Rewards |
| Poseida Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Precision BioSciences, Inc. | 115% | RSU 100 | not disclosed | Aon |
| Replimune Group, Inc. | not disclosed | not disclosed | No | Pearl Meyer |
| Sutro Biopharma, Inc. | 115% | Options 59 · RSU 41 | not disclosed | FW Cook |
| Vaxart Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (27 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Andrew Allen. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table” · page 25. As printed: 3,444,071. View filing ↗
- Section 01, Karin Jooss. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table” · page 25. As printed: 1,579,790. View filing ↗
- Section 01, Erin Jones. DEF 14A, filed 2024-04-29. Section “Summary Compensation Table” · page 25. As printed: 1,521,727. View filing ↗
- Section 08, Elaine Jones, Ph.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 175,999. View filing ↗
- Section 08, Steve Krognes. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 148,499. View filing ↗
- Section 08, Naiyer Rizvi, M.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 139,999. View filing ↗
- Section 08, Shefali Agarwal, M.D., M.P.H. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 138,499. View filing ↗
- Section 08, Clare Fisher. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 136,499. View filing ↗
- Section 08, Lawrence Corey, M.D. DEF 14A, filed 2024-04-29. Section “Director Compensation”. As printed: 132,499. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 341,000 + equity 0 + all other 0 = 341,000, summed across the director compensation table rows.
- Immunovant Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Replimune Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group, Inc.'s own proxy. As printed: 5,845,982. View filing ↗
- CytomX Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in CytomX Therapeutics, Inc.'s own proxy. As printed: 4,738,495. View filing ↗
- Kura Oncology Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology Inc.'s own proxy. As printed: 4,735,016. View filing ↗
- Poseida Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Poseida Therapeutics, Inc.'s own proxy. As printed: 3,818,018. View filing ↗
- Gritstone bio (subject), Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Gritstone bio's own proxy. As printed: 3,444,071. View filing ↗
- IGM Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences, Inc.'s own proxy. As printed: 3,207,328. View filing ↗
- Precision BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences, Inc.'s own proxy. As printed: 2,189,467. View filing ↗
- Evelo Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-28. CEO total compensation as printed in Evelo Biosciences, Inc.'s own proxy. As printed: 1,721,635. View filing ↗
- Arcturus Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Arcturus Therapeutics Inc.'s own proxy. As printed: 1,691,000. View filing ↗
- Sutro Biopharma, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Sutro Biopharma, Inc.'s own proxy. As printed: 1,671,311. View filing ↗
- Jounce Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Jounce Therapeutics, Inc.'s own proxy. As printed: 1,613,754. View filing ↗
- Arbutus Biopharma Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Arbutus Biopharma Corporation's own proxy. As printed: 1,369,013. View filing ↗
- Atara Biotherapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics Inc.'s own proxy. As printed: 1,068,069. View filing ↗
- Celularity Inc., Section 10b CEO total. DEF 14A, filed 2025-11-07. CEO total compensation as printed in Celularity Inc.'s own proxy. As printed: 848,959. View filing ↗
- Section 10a, Sutro Biopharma, Inc. reciprocity. DEF 14A. Sutro Biopharma, Inc. names Gritstone bio in its own disclosed peer group (read from its most recent proxy). View filing ↗